Skip to main content

Table 3 The proportion of households facing catastrophic payments for procuring antidiabetic medicines in rural and urban areas

From: Catastrophic pharmaceutical expenditure in patients with type 2 diabetes in Iran

Scenario

Treatment schedule

Rural (2%)

Rural (8%)

Urban (2%)

Urban (8%)

Monotherapy

Metformin

0%

0%

0%

0%

Glibenclamide

0%

0%

0%

0%

Gliclazide

0%

0%

0%

0%

Dual therapy

Metformin + Acarbose

0%

0%

0%

0%

Metformin + Repaglinide

4%

4%

0%

0%

Metformin + Glibenclamide

0%

0%

0%

0%

Metformin + Gliclazide

0%

0%

0%

0%

Metformin + Pioglitazone

4%

0%

0%

0%

Triple oral therapy

Metformin + Pioglitazone + Glibenclamde

4%

4%

0%

0%

Metformin + Pioglitazone + Gliclazide

4%

4%

0%

0%

Metformin + Pioglitazone + Acarbose

4%

4%

0%

0%

Oral therapy + Insulin

Metformin + Insulin isophane

4%

4%

4%

0%

Metformin + Insulin glargine

46%

12%

22%

4%

Metformin + Insulin detemir

94%

56%

90%

31%